Opthea Limited ADR (OPT)

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

GlobeNewswire Inc.

Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)

GlobeNewswire Inc.

Opthea To Present at Clinical Trials at the Summit Meeting

GlobeNewswire Inc.

Market Insight: Opthea Limited ADR (OPT)'s Notable Drop, Closing at 3.00 – DWinneX - The Dwinnex

The Dwinnex

Market Insight: Opthea Limited ADR (OPT)'s Notable Drop, Closing at 3.00 – DWinneX - The Dwinnex

The Dwinnex

2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart

Barchart

Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

GlobeNewswire Inc.

2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart

Barchart

Opthea (NASDAQ:OPT) Shares Down 0.6% - Defense World

Defense World

2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart

Barchart

Optiva Inc. Reports First Quarter 2024 Financial Results

GlobeNewswire Inc.

Opthea Announces Upcoming Presentations at the Retina World Congress 2024

GlobeNewswire Inc.

Optiva and GDi Announce Strategic Partnership to Deliver Integrated BSS and OSS Solutions

GlobeNewswire Inc.

Opthea Appoints John Han, PharmD, as VP Medical Affairs

GlobeNewswire Inc.

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference 

GlobeNewswire Inc.

Opthea Appoints Sujal Shah to the Board of Directors

GlobeNewswire Inc.

Opthea appoints new director and audit chair By Investing.com - Investing.com

Investing.com

11 Best ASX Stocks To Buy Now - Yahoo Finance

Yahoo Finance

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

GlobeNewswire Inc.

Optiva Inc. Reports Fourth Quarter 2023 Financial Results

GlobeNewswire Inc.

Opthea to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire Inc.

Opthea Reports Half-Year Financial Results and Business Updates

GlobeNewswire Inc.

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

GlobeNewswire Inc.

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

GlobeNewswire Inc.

10 Best Australian Stocks To Buy - Yahoo Finance

Yahoo Finance

Opthea Strengthens Team with Key Clinical and Regulatory Hires

GlobeNewswire Inc.

Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

Benzinga

Optiva Reports Preliminary Fourth Quarter and Full Year 2023 Revenue, and Provides Growth Outlook for 2024

GlobeNewswire Inc.

Opthea to Receive US$35M Commitment and Additional US$50M Funding

GlobeNewswire Inc.

Opthea Receives A$8.8 million R&D Tax Incentive

GlobeNewswire Inc.

AAO 2023: ShORe and COAST clinical trial updates from Opthea Limited - Ophthalmology Times Europe

Ophthalmology Times Europe

Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends - Stockhead

Stockhead

Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead

Stockhead

Biotech Company Opthea Aims To Raise $160M In US IPO - Yahoo Finance

Yahoo Finance

Biotech Company Opthea Aims To Raise $160M In US IPO - Yahoo Finance

Yahoo Finance

Opthea Limited ADR (CKDXY) OPT-302: Phase 1/2A wet AMD Trial Update - Slideshow (NASDAQ:OPT) - Seeking Alpha

Seeking Alpha